As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
10 Analysts have issued a Anixa Biosciences, Inc. forecast:
10 Analysts have issued a Anixa Biosciences, Inc. forecast:
| Jul '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -12 -12 |
13%
13%
|
|
| Net Profit | -11 -11 |
10%
10%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
| Head office | United States |
| CEO | Amit Kumar |
| Employees | 5 |
| Founded | 1982 |
| Website | www.anixa.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


